Literature DB >> 12133113

Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment?

Dennis E McChargue1, Suzy B Gulliver, Brian Hitsman.   

Abstract

We evaluated literature that addresses the notion that flexible smoking treatment approaches are warranted for smokers with a diagnosis of schizophrenia. Understanding the biological and psychological mechanisms that increase the likelihood of smoking and decrease the motivation to quit for these individuals is addressed within the framework of a neurobiological model. We provide a brief overview of the limited smoking cessation treatment literature for patients with schizophrenia and compare abstinence-focused versus reduction-focused treatment modalities. The potential utility of the reduction-focused approach to tobacco treatment for these smokers is evaluated. Suggestions for future research to address the utility and efficacy of reduction-focused interventions for smokers with schizophrenia are put forth. We conclude with a consideration of the implications for the current understanding of smoking treatment among patients with co-morbid psychiatric diagnoses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133113     DOI: 10.1046/j.1360-0443.2002.00064.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  16 in total

1.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

2.  A smoking ban in psychiatric units: threat or opportunity?

Authors:  Lindsay Banham; Simon Gilbody; Helen Lester
Journal:  Ment Health Fam Med       Date:  2008-09

3.  Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder.

Authors:  Jill M Williams; Marc L Steinberg; Mia Hanos Zimmermann; Kunal K Gandhi; Brooke Stipelman; Patricia Dooley Budsock; Douglas M Ziedonis
Journal:  J Subst Abuse Treat       Date:  2010-04-02

Review 4.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

5.  The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia.

Authors:  Christopher G Ahnallen; Gabrielle I Liverant; Kristin L Gregor; Barbara W Kamholz; James J Levitt; Suzy Bird Gulliver; Diego A Pizzagalli; Vamsi K Koneru; Gary B Kaplan
Journal:  Psychiatry Res       Date:  2012-02-17       Impact factor: 3.222

Review 6.  A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities.

Authors:  Taryn G Moss; Andrea H Weinberger; Jennifer C Vessicchio; Vincenza Mancuso; Sandra J Cushing; Michael Pett; Kate Kitchen; Peter Selby; Tony P George
Journal:  Am J Addict       Date:  2010 Jul-Aug

7.  Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow
Journal:  Schizophr Res       Date:  2009-12       Impact factor: 4.939

8.  Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia.

Authors:  Kuan-Ju Chou; Hsing-Kang Chen; Chih-Hung Hung; Tzu-Ting Chen; Chun-Ming Chen; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-07-09       Impact factor: 5.270

Review 9.  Treatment of tobacco dependence in mental health and addictive disorders.

Authors:  Brian Hitsman; Taryn G Moss; Ivan D Montoya; Tony P George
Journal:  Can J Psychiatry       Date:  2009-06       Impact factor: 4.356

10.  A randomized controlled trial of a smoking cessation intervention conducted among prisoners.

Authors:  Robyn Richmond; Devon Indig; Tony Butler; Kay Wilhelm; Vicki Archer; Alex Wodak
Journal:  Addiction       Date:  2013-03-11       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.